The project led by Prof. Dr. Ayşegül Gümüş, a faculty member of our department, has been selected for funding under the TÜBİTAK 1002-A Rapid Support Program.

The project, titled "Synthesis of New Coumarin-Quinoline Derivatives, Investigation of Cholinesterase Enzyme Inhibition and Antioxidant Effects, and Computational Studies," aims to inhibit certain enzymes involved in Alzheimer's disease. Within this scope, novel hybrid compounds will be developed, and their enzyme inhibition capacities and antioxidant effects will be evaluated both in laboratory settings and through computer-aided analyses.

The project team includes Prof. Dr. Dursun Kısa from the Department of Molecular Biology and Genetics, Faculty of Science; Prof. Dr. Selçuk Gümüş from the Department of Basic Sciences, Faculty of Engineering, Architecture and Design; and Burçin Karahan Özdemir, a graduate student in the Department of Biotechnology.

Commenting on the project, Prof. Dr. Ayşegül Gümüş stated: "With this project, we aim to develop new hybrid compounds for the inhibition of acetylcholinesterase and butyrylcholinesterase enzymes, which play a significant role in Alzheimer's disease. We will investigate the enzyme inhibition capacities and antioxidant effects of these compounds and perform computational analyses. We ultimately aim to contribute to the treatment of this disease."

BARÜ Rector Prof. Dr. Ahmet Akkaya congratulated Prof. Dr. Ayşegül Gümüş and the project team for developing innovative solutions addressing needs in the field of healthcare, and wished them continued success.